AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36562609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk signature
Number of subjects: 56
Study 36562609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk prediction model
Number of subjects: 56
Study 36562831 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin arm (n=15) - received letrozole 2.5 mg/day plus metformin (2000±500 mg/day)
Number of subjects: 45
Study 36562831 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=15) - received letrozole 2.5 mg/day
Number of subjects: 45
Study 36562831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean arm (n=15) - received letrozole 2.5 mg/day
Number of subjects: 45
Study 36562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of elamipretide
Number of subjects: 30
Study 36562873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36563028 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld weights of a maximum of 4 kg during 30° arm abduction and adduction trials
Number of subjects: 0
Study 36563028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric shoulder muscle strength assessment with a dynamometer
Number of subjects: 0
Study 36563028 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder magnetic resonance imaging
Number of subjects: 0
Study 36563086 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TEST; 200 mg·wk -1)
Number of subjects: 50
Study 36563086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study 36563458 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scoring (Coronary Artery Calcium scoring)
Number of subjects: 1904
Study 36563458 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scoring
Number of subjects: 1904
Study 36563712 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic risk factors (n=479)
Number of subjects: 851
Study 36563712 — intervention group
Group type: COMPARATOR
Intervention: Anatomic risk factors (n=372)
Number of subjects: 851
Study 36563712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes (stroke, death, MI)
Number of subjects: 851
Study 36563874 — intervention group
Group type: EXPERIMENTAL
Intervention: Frustration-induction task during functional magnetic resonance imaging
Number of subjects: 66
Study 36563874 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfrustration recovery period
Number of subjects: 66
Study 36563879 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotitrating positive airway pressure
Number of subjects: 241
Study 36563879 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene controls
Number of subjects: 241
Study 36563879 — intervention group
Group type: COMPARATOR
Intervention: Sham positive airway pressure control
Number of subjects: 241
Study 36563964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AMD (iAMD) study eyes
Number of subjects: 301
Study 36563964 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study cohort
Number of subjects: 301
Study 36564033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary lithium excretion
Number of subjects: 642
Study 36564047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus brentuximab vedotin (BV)
Number of subjects: 44
Study 36564047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine
Number of subjects: 44
Study 36564099 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2)
Number of subjects: 65
Study 36564099 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2) in patients with high mesothelin expression
Number of subjects: 65
Study 36564114 — intervention group
Group type: EXPERIMENTAL
Intervention: Two individual sweeteners and two sweetness enhancer blends in solid and semi-solid foods
Number of subjects: 213
Study 36564114 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-sweetened control
Number of subjects: 213
Study 36564119 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound (TUS)
Number of subjects: 80
Study 36564119 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers surfactant protein-D and microfibrillar-associated protein 4
Number of subjects: 80
Study 36564123 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 200
Study 36564123 — intervention group
Group type: COMPARATOR
Intervention: placebo (switching to guselkumab 100 mg at week 24)
Number of subjects: 200
Study 36564123 — intervention group
Group type: COMPARATOR
Intervention: non-biological standard of care
Number of subjects: 200
Study 36564126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral V937 plus intravenous ipilimumab 3 mg/kg Q3W for four doses starting on day 22.
Number of subjects: 50
Study 36564148 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health platform intervention (access to health information website for 16 weeks)
Number of subjects: 135
Study 36564148 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued training as normal)
Number of subjects: 135
Study 36564247 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted changes to airway management strategies
Number of subjects: 0
Study 36564247 — intervention group
Group type: COMPARATOR
Intervention: Difficult bag-mask ventilation
Number of subjects: 0
Study 36564247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube-related event
Number of subjects: 0
Study 36564274 — intervention group
Group type: EXPERIMENTAL
Intervention: AS37 adjuvanted vaccine
Number of subjects: 0
Study 36564274 — intervention group
Group type: COMPARATOR
Intervention: Licensed alum-adjuvanted meningococcal serogroup C (MenC-CRM) vaccine
Number of subjects: 0
Study 36564395 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (100 mg)
Number of subjects: 16
Study 36564395 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (100 mg) and Rifampin (600 mg)
Number of subjects: 16
Study 36564395 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (600 mg)
Number of subjects: 16
Study 36564535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 28
Study 36564576 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA CE 0.1% QID (high-dose; n=96)
Number of subjects: 387
Study 36564576 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA CE 0.05% QID and CsA CE 0.1% BID (low-dose; n=93)
Number of subjects: 387
Study 36564576 — intervention group
Group type: COMPARATOR
Intervention: Vehicle QID (vehicle; n=98)
Number of subjects: 387
Study 36564644 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care intervention (TCI) including discharge transportation with a home visit, post-discharge cross-sectorial video conference, and seven-day telephone consultation.
Number of subjects: 1205
Study 36564644 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1205
Study 36564644 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care intervention (TCI).
Number of subjects: 1205
Study 36564733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 694
Study 36564769 — intervention group
Group type: EXPERIMENTAL
Intervention: e-EDUCAGUIA strategy (game-based educational strategy)
Number of subjects: 202
Study 36564769 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of the guideline (control)
Number of subjects: 202
Study 36564795 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-responsive implementation strategy training for HIV providers
Number of subjects: 240
Study 36564795 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 240
Study 36564802 — intervention group
Group type: EXPERIMENTAL
Intervention: Arts-based HIV-related stigma intervention delivered by community Elders and supported by teachers, with a focus on local cultural knowledge and practices.
Number of subjects: 1800
Study 36564802 — intervention group
Group type: COMPARATOR
Intervention: Control group (government-funded schools not receiving the intervention during the initial phase).
Number of subjects: 1800
Study 36564808 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece SBT
Number of subjects: 108
Study 36564808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen SBT
Number of subjects: 108
Study 36564825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (Jemperli, GlaxoSmithKline)
Number of subjects: 12
Study 36564852 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Health = Family Wealth intervention (n=35 couples)
Number of subjects: 140
Study 36564852 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched water, sanitation, and hygiene (WASH) intervention (n=35 couples)
Number of subjects: 140
Study 36564955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g once daily for 12 weeks
Number of subjects: 182
Study 36564955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 36564955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SZC and placebo)
Number of subjects: 182
Study 36565045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester (d-β-hydroxybutyrate-(R)-1,3 butanediol) drink
Number of subjects: 18
Study 36565045 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 18
Study 36565044 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) revascularization technique
Number of subjects: 28
Study 36565044 — intervention group
Group type: COMPARATOR
Intervention: Conventional endodontic treatment (control group)
Number of subjects: 28
Study 36565044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PRP and conventional treatment)
Number of subjects: 28
Study 36565156 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week, supervised, multi-component exercise program
Number of subjects: 100
Study 36565181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (50 mmol NaCl/24 h)
Number of subjects: 40
Study 36565181 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet (250 mmol NaCl/24 h)
Number of subjects: 40
Study 36565187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) subclasses
Number of subjects: 4019
Study 36565189 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) defined as P2Y12 reaction units >208
Number of subjects: 8582
Study 36565189 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus
Number of subjects: 8582
Study 36565189 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes mellitus
Number of subjects: 8582
Study 36565198 — intervention group
Group type: EXPERIMENTAL
Intervention: MINOCA
Number of subjects: 554
Study 36565199 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730
Study 36565199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 36565462 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Self-Management After Recent Traumatic brain injury) program
Number of subjects: 71
Study 36565462 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 71
Study 36565721 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 6836
Study 36565721 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 6836
Study 36565721 — intervention group
Group type: COMPARATOR
Intervention: Conventional erythropoiesis-stimulating agents (ESAs)
Number of subjects: 6836
Study 36565956 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGRESS-CTO complication risk scores
Number of subjects: 4569
Study 36566079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily tenofovir alafenamide (25 mg) (group 1)
Number of subjects: 183
Study 36566079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily bictegravir (75 mg) (group 2)
Number of subjects: 183
Study 36566079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily lenacapavir (600 mg on days 1 and 2, followed by 50 mg daily) with emtricitabine (200 mg) and tenofovir alafenamide (25 mg) (group 3)
Number of subjects: 183
Study 36566079 — intervention group
Group type: COMPARATOR
Intervention: Oral daily bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) (group 4)
Number of subjects: 183
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pulse oxygen saturation < 96%
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant tumor metastasis
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Miles procedure or left hemicolectomy
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative surgical events
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative albumin infusion
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative early ambulation
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative albumin infusion in patients with preoperative albumin level < 40 g/L
Number of subjects: 280
Study 36566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative albumin infusion in patients with duration of surgery ≥ 3 h
Number of subjects: 280
Study 36566192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy (MHL; 6 h)
Number of subjects: 1032
Study 36566192 — intervention group
Group type: EXPERIMENTAL
Intervention: MHL plus a first-person Stigma Reduction Programme (MHL + SR; 7 h)
Number of subjects: 1032
Study 36566192 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity Programme (SP; 1 h)
Number of subjects: 1032
Study 36566192 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): waiting list
Number of subjects: 1032
Study 36566202 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel applied twice daily (BID)
Number of subjects: 302
Study 36566202 — intervention group
Group type: COMPARATOR
Intervention: DDEA 1.16% gel applied four times daily (QID)
Number of subjects: 302
Study 36566202 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 302
Study 36566202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 302
Study 36566266 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 150
Study 36566266 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF-MEK inhibitors
Number of subjects: 150
Study 36566266 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 60 years, cardiovascular disorders, diabetes mellitus
Number of subjects: 150
Study 36566266 — intervention group
Group type: COMPARATOR
Intervention: Advanced melanoma stage, melanoma systemic therapies
Number of subjects: 150
Study 36566274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GABA twice-daily (n=41)
Number of subjects: 97
Study 36566274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GABA plus two-doses GAD-alum (n=25)
Number of subjects: 97
Study 36566274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=31)
Number of subjects: 97
Study 36566304 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA score
Number of subjects: 7119
Study 36566304 — intervention group
Group type: COMPARATOR
Intervention: IMPROVE score
Number of subjects: 7119
Study 36566344 — intervention group
Group type: EXPERIMENTAL
Intervention: AK111 75 mg
Number of subjects: 48
Study 36566344 — intervention group
Group type: EXPERIMENTAL
Intervention: AK111 150 mg
Number of subjects: 48
Study 36566344 — intervention group
Group type: EXPERIMENTAL
Intervention: AK111 300 mg
Number of subjects: 48
Study 36566344 — intervention group
Group type: EXPERIMENTAL
Intervention: AK111 450 mg
Number of subjects: 48
Study 36566344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36566574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated LN metastases
Number of subjects: 20
Study 36566574 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional extranodal metastases
Number of subjects: 20
Study 36566574 — intervention group
Group type: COMPARATOR
Intervention: LN sampling at initial diagnosis
Number of subjects: 20
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiocephalic arteriovenous fistula creation
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous side-branch ligation
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Open revisions
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to restore or maintain patency
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to assist maturation
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve depth
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve augmentation
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative vein diameter <3.0 mm
Number of subjects: 914
Study 36567000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not on hemodialysis at the time of fistula creation
Number of subjects: 914
Study 36567058 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-supported self-help CBTi (Tele-Self CBTi)
Number of subjects: 0
Study 36567058 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 0
Study 36567076 — intervention group
Group type: EXPERIMENTAL
Intervention: e-RPT (web-based relapse prevention therapy)
Number of subjects: 60
Study 36567076 — intervention group
Group type: COMPARATOR
Intervention: face-to-face RPT (traditional relapse prevention therapy)
Number of subjects: 60
Study 36567076 — intervention group
Group type: EXPERIMENTAL
Intervention: e-RPT
Number of subjects: 60
Study 36567076 — intervention group
Group type: COMPARATOR
Intervention: face-to-face RPT
Number of subjects: 60
Study 36567173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Blood Glucose Control (IBGC)
Number of subjects: 41
Study 36567173 — intervention group
Group type: COMPARATOR
Intervention: Standard Blood Glucose Control (SBGC)
Number of subjects: 41
Study 36567211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab); median treatment duration 3.3 months
Number of subjects: 232
Study 36567211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab)
Number of subjects: 232
Study 36567243 — intervention group
Group type: COMPARATOR
Intervention: early ODT
Number of subjects: 30
Study 36567243 — intervention group
Group type: EXPERIMENTAL
Intervention: early DBS+ODT
Number of subjects: 30
Study 36567264 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge training
Number of subjects: 78
Study 36567264 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 78
Study 36567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive clinical assessments including physical and psychosocial factors, movement assessments via a semi-automated markerless motion capture system, joint range of motion assessments, psychosocial measures, and self-reported physical fitness performance and MSKI history.
Number of subjects: 1340
Study 36567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial assessments at enrollment, 4 weeks post-enrollment, and 12 weeks post-enrollment for the second cohort.
Number of subjects: 1340
Study 36567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum set of clinical assessments to personalize MSKI risk mitigation and rehabilitation strategies.
Number of subjects: 1340
Study 36567351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen 1/100
Number of subjects: 105
Study 36567351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen 1/1000
Number of subjects: 105
Study 36567351 — intervention group
Group type: COMPARATOR
Intervention: Intralesional zinc sulfate 2%
Number of subjects: 105
Study 36567347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with higher airway pressures
Number of subjects: 391
Study 36567347 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 391
Study 36567347 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors
Number of subjects: 391
Study 36568164 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 36
Study 36568239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks intravenously until disease progression, unacceptable toxicity, or withdrawal.
Number of subjects: 33
Study 36568250 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (75mg/m2/d on days 1-5 subcutaneous) combined with Homoharringtonine (HHT 2mg/m2/d on days 4-8 intravenous over 3 hours), Idarubicin (6mg/m2/d on days 4-6 intravenous), and Cytarabine (100mg/m2/d on days 4-10 intravenous)
Number of subjects: 20
Study 36568414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ACBMNC infusion (targeted at 5 × 10^7 cells)
Number of subjects: 120
Study 36568414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36568444 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised exercise intervention program
Number of subjects: 45